NCS Report 14: Quality control of sealed beta sources in brachytherapy

Kollaard, Robert; Dries, Wim; Kleffens, H.J. van; Aalbers, A.H.L.; Marel, J. van der; Marijnissen, Johannes P. A.; Piessens, Marleen; Schaart, Dennis R.; Vroome, Henk de

doi:10.25030/ncs-014

Cited by 5 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time BEBIG introduced improved manufacturing processes, but a recent publication [24] however still reported source non-uniformities of 13%-20%. Following the 2002 NIST calibration 106 Ru eye plaque dosimetry was extensively reviewed by ICRU 72 [25], Netherlands Report on Beta Dosimetry [26] and ISO Standard 21439:2009 [10]. The latter standard while not excluding other methods, selected as recommended methods for beta dosimetry radiochromic film, plastic scintillators, silicon diodes and TLDs.…”

Section: Introductionmentioning

confidence: 99%

15 years of ¹⁰⁶ Ru eye plaque dosimetry at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center using radiochromic film in a Solid Water phantom

Trichter

Soares

Zaider

et al. 2018

Biomed. Phys. Eng. Express

View full text Add to dashboard Cite

Purpose. 106 Ru eye plaques are used for treatment of intraocular malignancies, providing a good alternative to enucleation. We perform our own acceptance testing and commissioning of 106 Ru eye plaques using radiochromic film as recommended by ISO standard 21439:2009 'Clinical dosimetrybeta radiation sources for brachytherapy'. A Solid Water 'eye' phantom with several novel features and related tools were developed for accurate radiochromic film dosimetry of eye plaques. Methods. The phantom enables full 3D dosimetric characterization of eye plaques. Films perpendicular to the central axis of the eye plaques are sandwiched between inserts in the phantom. Small holes in the phantom inserts enable marking the films with respect to the eye plaques, assuring exact geometrical coregistration. Special thin unlaminated radiochromic films were utilized, enabling dosimetric measurements virtually at the surface of the eye plaques. Precise film punches were developed in order to cut films with diameters as small as 8.5 mm and make cutouts in films without damaging the cut edges. Results. Full dosimetric characterization of three CCX type and partial characterization of a CIA type 106 Ru eye plaques is presented. Replicate film results were reproducible to within 4%-5%. Even 4% non-uniformities in planar dose rates were easily detected. Comparison with Monte Carlo calculations by Hermida-López 2013 Med. Phys. 40 101705-1-101705-13, found good agreement along the central axis, but some lateral differences. Conclusions. Accurate and precise 106 Ru eye plaque dosimetry was achieved utilizing radiochromic film in the phantom introduced here. Co-registration of eye plaques and films permits not only precise treatment planning calculations along the central axis of the plaque, but also accounts for dosimetric non-uniformities using 2D or 3D methodologies. Dose measurements on the inner surface of the plaques provide precise assessment of the scleral dose, its homogeneity, and the active area of the plaques for coverage determination.

show abstract

Section: Introductionmentioning

confidence: 99%

15 years of ¹⁰⁶ Ru eye plaque dosimetry at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center using radiochromic film in a Solid Water phantom

Trichter

Soares

Zaider

et al. 2018

Biomed. Phys. Eng. Express

View full text Add to dashboard Cite

show abstract

“…These measurements were carried out with a 2 mm diameter and 2 mm thick plastic scintillator: the stated uncertainty was 30%. However, differences exceeding a factor of two were observed relative to the manufacturer's stated dose‐rate values on the plaque central axis …”

Section: Quality Management and Assurance Processes For Ocular Plaque Bmentioning

confidence: 96%

“…The aforementioned MC results are for idealized sources with uniform radioactivity distributions. Actual sources may have non‐uniformities in the radionuclide distribution that might influence relative depth dose profiles, and thus MC results that assume a uniform activity distribution should be used for guidance only and should not be used in place of dosimetry measurements …”

Section: Review Of Dosimetric Studies For Various Plaque Modelsmentioning

confidence: 99%

AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221

et al. 2020

View full text Add to dashboard Cite

The American Association of Physicists in Medicine (AAPM) formed Task Group 221 (TG-221) to discuss a generalized commissioning process, quality management considerations, and clinical physics practice standards for ocular plaque brachytherapy. The purpose of this report is also, in part, to aid the clinician to implement recommendations of the AAPM TG-129 report, which placed emphasis on dosimetric considerations for ocular brachytherapy applicators used in the Collaborative Ocular Melanoma Study (COMS). This report is intended to assist medical physicists in establishing a new ocular brachytherapy program and, for existing programs, in reviewing and updating clinical practices. The report scope includes photon-and beta-emitting sources and source:applicator combinations. Dosimetric studies for photon and beta sources are reviewed to summarize the salient issues and provide references for additional study. The components of an ocular plaque brachytherapy quality management program are discussed, including radiation safety considerations, source calibration methodology, applicator commissioning, imaging quality assurance tests for treatment planning, treatment planning strategies, and treatment planning system commissioning. Finally, specific guidelines for commissioning an ocular plaque brachytherapy program, clinical physics practice standards in ocular plaque brachytherapy, and other areas reflecting the need for specialized treatment planning systems, measurement phantoms, and detectors (among other topics) to support the clinical practice of ocular brachytherapy are presented. Expected future advances and developments for ocular brachytherapy are discussed.

show abstract

“…Iridium wires, Cesium sources as well as beta sources for coronary brachytherapy are not used in the Netherlands and Belgium anymore so these are not discussed in this report. Other types of brachytherapy, such as Iodine-implants, are dealt with in other NCS reports [12,13]. Dose calculations, a major topic in all three previous NCS-reports, are not dealt with in this report.…”

Section: Introductionmentioning

confidence: 99%

NCS Report 30: Code of Practice for Quality Assurance of Brachytherapy with Ir-192 Afterloaders

Steenhuizen¹,

Harbers²,

Hoffmann³

et al. 2018

View full text Add to dashboard Cite

NCS Report 14: Quality control of sealed beta sources in brachytherapy

Cited by 5 publications

References 62 publications

15 years of ¹⁰⁶ Ru eye plaque dosimetry at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center using radiochromic film in a Solid Water phantom

15 years of ¹⁰⁶ Ru eye plaque dosimetry at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center using radiochromic film in a Solid Water phantom

AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221

NCS Report 30: Code of Practice for Quality Assurance of Brachytherapy with Ir-192 Afterloaders

Contact Info

Product

Resources

About

NCS Report 14: Quality control of sealed beta sources in brachytherapy

Cited by 5 publications

References 62 publications

15 years of 106 Ru eye plaque dosimetry at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center using radiochromic film in a Solid Water phantom

15 years of 106 Ru eye plaque dosimetry at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center using radiochromic film in a Solid Water phantom

AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221

NCS Report 30: Code of Practice for Quality Assurance of Brachytherapy with Ir-192 Afterloaders

Contact Info

Product

Resources

About

15 years of ¹⁰⁶ Ru eye plaque dosimetry at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center using radiochromic film in a Solid Water phantom

15 years of ¹⁰⁶ Ru eye plaque dosimetry at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center using radiochromic film in a Solid Water phantom